(MedPage Today) — No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ panel.
In a new “living” guideline…
Source link : https://www.medpagetoday.com/endocrinology/diabetes/117003
Author :
Publish date : 2025-08-14 22:30:00
Copyright for syndicated content belongs to the linked Source.
